Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma.
Sign Up to like & getrecommendations! Published in 2024 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2024.1113
Abstract: This cohort study examines the role of comprehensive bridging radiotherapy in the setting of chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. read more here.
Keywords: non hodgkin; bridging radiotherapy; hodgkin lymphoma; comprehensive bridging ... See more keywords
Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non‐Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2025 at "Advanced Materials"
DOI: 10.1002/adma.202502372
Abstract: Lymphoma, a common malignancy of the lymphatic system, presents considerable health challenges and imposes a significant economic burden. Despite advancements in chemotherapy and immunotherapy that have improved survival rates, issues such as high relapse rates… read more here.
Keywords: non hodgkin; relapse; treatment; tumor ... See more keywords
No association of malignant B‐cell non‐Hodgkin lymphomas with ipsilateral SARS‐CoV‐2 vaccination
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5687
Abstract: SARS‐CoV‐2 vaccines cause acute ipsilateral lymph node swelling in an important proportion of vaccines. Thus far, no malignant lymphadenopathies have been reported in temporal context to vaccination in the ipsilateral draining lymph node areas. read more here.
Keywords: non hodgkin; vaccination; association malignant; cell non ... See more keywords
Global burden, risk factors, and trends of non‐Hodgkin lymphoma: A worldwide analysis of cancer registries
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.7056
Abstract: Non‐Hodgkin lymphoma (NHL) accounts for 90% of all malignant lymphomas. This study aimed to evaluate the global incidence, mortality, associated risk factors, and temporal trends of NHL by sex, age, and country. read more here.
Keywords: non hodgkin; cancer; hodgkin lymphoma; risk factors ... See more keywords
Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.71405
Abstract: Therapeutic advances in primary gastrointestinal non‐Hodgkin lymphoma (PGI‐NHL) have improved patient prognosis but also raised concerns regarding long‐term health outcomes. This study assesses patterns of second primary cancers (SPCs) and cause‐specific mortality in PGI‐NHL survivors. read more here.
Keywords: non hodgkin; gastrointestinal non; primary gastrointestinal; cause specific ... See more keywords
Risk of venous thromboembolism in patients with non‐Hodgkin lymphoma surviving blood or marrow transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32488
Abstract: Patients with non‐Hodgkin lymphoma (NHL) have an increased risk of venous thromboembolism (VTE), particularly when they are receiving treatment. Blood or marrow transplantation (BMT) is recommended for relapsed/refractory NHL, and the risk of VTE after… read more here.
Keywords: risk venous; risk; hodgkin lymphoma; patients non ... See more keywords
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20).
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34822
Abstract: BACKGROUND Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC)… read more here.
Keywords: qlq; hodgkin lymphoma; non hodgkin; nhl hg29 ... See more keywords
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1133
Abstract: The pharmacokinetics (PK) and safety of ofatumumab and bendamustine alone and in combination were evaluated in patients with treatment‐naive or relapsed indolent B‐cell non‐Hodgkin lymphoma (iNHL). Patients were randomly assigned to ofatumumab and bendamustine or… read more here.
Keywords: hodgkin lymphoma; non hodgkin; indolent cell; concentration ... See more keywords
cDC2 and plasmacytoid dendritic cells diminish from tissues of patients with non‐Hodgkin orbital lymphoma and idiopathic orbital inflammation
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Immunology"
DOI: 10.1002/eji.201948370
Abstract: Non‐Hodgkin orbital lymphoma (NHOL) and idiopathic orbital inflammation (IOI) are common orbital conditions with largely unknown pathophysiology. To investigate the immune cell composition of these diseases, we performed standardized 29 parameter flow cytometry phenotyping in… read more here.
Keywords: orbital lymphoma; non hodgkin; dendritic cells; ioi patients ... See more keywords
UPFRONT AHSCT IN NON HODGKIN LYMPHOMA‐BETTER OUTCOME?
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.108_2631
Abstract: and Clinical Study registry NIHIL (govTrial no: NCT03199066). Basic characteristics are summarized in Table 1. The clinical outcomes of DA-EPOCH-R cohort were compared to 117 pts treated with RCHOP regimen from 2 centres where intensification… read more here.
Keywords: pfs; hodgkin lymphoma; ahsct non; lymphoma better ... See more keywords
CT‐P10 RAPID INFUSION IN PATIENTS WITH NON‐HODGKIN'S LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKAEMIA: INTERIM RESULTS FROM A NON‐INTERVENTIONAL POST‐AUTHORISATION SAFETY STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.224_2631
Abstract: 30 [76.7%] versus 125 of 214 [58.4%]). Requests for OLU for lymphoma patients were less frequently rejected by health insurers (3 of 30 [10.0%] versus 64 of 214 [29.9%]). In two cases, OLU of the… read more here.
Keywords: rapid infusion; non hodgkin; patients non; lymphoma ... See more keywords